Tag Archives: biotech industry

Herbicides and 2, 4-D: Cutting Through the Controversy

admin-ajax (2)

A number of media outlets reported on last week’s decision by the USDA to approve the use of genetically modified corn and soybean seeds that are resistant to the herbicide known as 2, 4-D. Farmers and growers, anxious for new tools in the ever-evolving fight against weeds, have been long awaiting the approval. The American Soybean Association, for example, issued a statement cheering the move and calling on the Environmental Protection Agency (EPA) to now Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Scientific Community Urges Obama to Support Biotechnology

admin-ajax

A number of media outlets are reporting today on a letter to President Obama urging approval for the genetically engineered AquAdvantage® Salmon and for more support for the innovative solutions that animal biotechnology can provide. Ninety scientists and biotechnology executives signed the letter asking the President to alleviate the political gridlock that has entangled the fish for years. The AquAdvantage® Salmon, genetically engineered to reach market size in half the time of a conventional Atlantic Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

PTO Patent Examinations in the wake of Mayo and Myriad

stopped-media-115x76

Biotech patent applicants are finding themselves in uncharted waters.   After the Supreme Court’s decisions in Mayo Collaborative Svs. v. Prometheus Labs and Ass’n for Molecular Pathology v. Myriad Genetics, companies have been trying to understand how these decisions will impact the industry. A recent study supported by BIO, in collaboration with Bloomberg BNA and the law firm of Robins, Kaplan, Miller & Ciresi analyzed how Mayo and Myriad have changed patent eligibility for biotechnology. Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , ,

Therapeutic Licensing and M&A Deals

lab_tech

Licensing deals for therapeutic candidates in 2013 dropped to the lowest volume in at least eight years for deals with disclosed values totaling over $10M. Total upfront payments to biotechs were also at an eight year low, with only $1.9B paid to biotechs in 2013. This is a 50 percent drop from peak levels. However, there is a silver lining in the data: Preclinical deal volume saw a slight increase in 2013, and has not Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

Some People Get it, and Some Just Don’t

admin-ajax (2)

As a communications director in the agriculture industry, I have spent two decades using fact-based talking points while industry opponents can say whatever will make a headline. It’s frustrating, but we labor on because we believe that what we do somehow helps farmers. And if we can help farmers, we can help keep America’s food supply safe, affordable and the envy of the world. Holly Spangler, an ag communicator and Illinois farmer, clearly understands this Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,